MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
PerkinElmer Revenue 2011-2026 | PKI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue PerkinElmer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.86 B | 2.76 B | 2.75 B | 3.83 B | 861 M | - | 2.88 B | 2.78 B | 2.12 B | 2.1 B | - | 2.24 B | 2.17 B | 1.92 B | 1.7 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.83 B | 861 M | 2.38 B |
Quarterly Revenue PerkinElmer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 699 M | 720 M | 665 M | - | 684 M | 692 M | 650 M | - | 671 M | 709 M | 675 M | - | 712 M | 896 M | 963 M | 1.35 B | 861 M | 1.23 B | 1.31 B | - | 964 M | 812 M | 652 M | 805 M | 707 M | 723 M | 649 M | 756 M | 674 M | 703 M | 644 M | 642 M | 554 M | 547 M | 514 M | 570 M | 514 M | 536 M | 498 M | - | 563 M | 564 M | 527 M | 608 M | 542 M | 556 M | 531 M | 592 M | 522 M | 541 M | 505 M | 573 M | 510 M | 522 M | 511 M | 470 M | 453 M | 479 M | 447 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.35 B | 447 M | 666 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
41 M | $ 13.65 | -0.44 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
568 M | $ 8.87 | 2.9 % | $ 591 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 151.97 | -2.34 % | $ 7.53 B | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 25.83 | 1.06 % | $ 717 M | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 17.32 | 1.82 % | $ 923 M | USA |
 |
DexCom
DXCM
|
4.66 B | $ 66.34 | 3.27 % | $ 25.9 B | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | $ 103.85 | 0.27 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
283 M | $ 14.95 | 1.22 % | $ 452 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
71.3 M | $ 17.29 | -3.3 % | $ 2.24 B | USA |
 |
Guardant Health
GH
|
982 M | $ 87.18 | 1.98 % | $ 10.9 B | USA |
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.84 | 0.35 % | $ 92.2 K | USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 191.39 | 2.17 % | $ 136 B | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 97.61 | -0.73 % | $ 8.05 B |  Irlanda |
 |
IQVIA Holdings
IQV
|
16.3 B | $ 164.89 | 0.1 % | $ 28.3 B | USA |
 |
Illumina
ILMN
|
4.37 B | $ 119.28 | 0.29 % | $ 19 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 198.94 | -0.38 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
6.32 B | $ 111.83 | 0.28 % | $ 34 B | USA |
 |
BioNano Genomics
BNGO
|
30.8 M | $ 1.11 | - | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
20.4 M | $ 8.42 | -6.44 % | $ 239 M | Israel |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 78.5 | -1.25 % | $ 5.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
6.81 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 453.64 | 0.72 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 198.71 | 2.13 % | $ 24.7 B |  Schweiz |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Neogen Corporation
NEOG
|
895 M | $ 9.11 | 0.22 % | $ 1.98 B | USA |
 |
National Research Corporation
NRC
|
137 M | $ 17.4 | 5.33 % | $ 389 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 8.24 | 4.57 % | $ 1.06 B | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
820 M | $ 197.68 | 5.23 % | $ 19.5 B | USA |
 |
OPKO Health
OPK
|
184 M | $ 1.19 | - | $ 826 M | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 1.36 | 2.26 % | $ 408 M | USA |